|
Patent landscape, scope, and claims: |
United States Patent 9,550,759 scope and claims: COMT-inhibitory oxadiazole nitrocatechol method claims and full US patent landscape
Patent 9,550,759 is a composition-adjacent and method-of-use estate built around orally administered COMT inhibitors of Formula (I), claimed broadly to increase brain delivery of L-DOPA and to inhibit peripheral COMT, and specifically to a single enumerated compound. The claims are drafted to capture: (i) oral co-administration with L-DOPA to increase the amount reaching the brain, (ii) inhibition of COMT “in the periphery,” (iii) reduction of L-DOPA O-methylation, and (iv) manufacturing/formulation of pharmaceutical compositions containing Formula (I).
What does US Patent 9,550,759 claim: Formula (I) COMT inhibitors for oral L-DOPA brain delivery?
Core claim architecture
US 9,550,759 contains eight claims, all tethered to Formula (I) COMT-inhibitory compounds and Parkinson’s disease (PD) therapeutic intent:
- Claim 1: method of increasing the amount of orally administered L-DOPA reaching the brain and treating PD by administering an oral “COMT-inhibitory effective amount” of a Formula (I) compound.
- Claim 3: method of inhibiting COMT in the periphery using the same Formula (I) compounds.
- Claim 7: method of reducing O-methylation of L-DOPA in PD patients treated with L-DOPA.
- Claims 2/4/6/8: the same single specific example compound is named in each of the independent method claim sets.
- Claim 5: method of manufacturing a pharmaceutical composition suitable for treating PD by formulating a Formula (I) compound with a pharmaceutically acceptable carrier.
Mechanistic tying language
Across the claim set, the “COMT-inhibitory effective amount” and downstream PD effect are tied through three functional outcomes:
- Brain delivery increase of orally administered L-DOPA (Claim 1).
- Peripheral COMT inhibition (Claim 3).
- Reduction of L-DOPA O-methylation (Claim 7).
This triangulation matters because it supports both:
- Pharmacodynamic infringement arguments (COMT inhibition/O-methylation), and
- Use-in-context arguments where an accused product is administered orally with L-DOPA for PD.
How broad are the claims in US 9,550,759: generic coverage from Markush-style Formula (I) to minimal structural constraints?
Breadth drivers: what is variable
The Formula (I) definition is a Markush-style framework with multiple variable regions:
- R1 and R2: hydrogen or optionally substituted lower alkanoyl or aroyl (small-to-moderate substituent flexibility).
- X: methylene group (fixed).
- Y: oxygen, NH, or sulfur (heteroatom swap flexibility).
- n: 0, 1, 2, or 3.
- m: 0 or 1.
- R3: a pyridine N-oxide connected via one of formulas A, B, or C (multiple regioisomeric N-oxide connectivities).
- P: central unit selected from regioisomers of 1,3,4-oxadiazol-2,5-diyl and 1,2,4-oxadiazol-3,5-diyl, and explicitly includes both regioisomers “realizable by exchange” of the nitrocatechol moiety and the —(X)n—(Y)m—R3 moiety.
- R4–R7: independently selected substituents including extensive ranges:
- hydrogen, C1–C6 alkyl, thioalkyl, alkoxy/aryloxy or thioaryl
- acyl/aryl acyl
- amino, alkylamino, dialkylamino
- cycloalkylamino, heterocycloalkylamino
- alkylsulphonyl or arylsulphonyl
- halogen, haloalkyl, trifluoromethyl, cyano, nitro
- heteroaryl
- plus the option that two or more residues together form rings (aliphatic/heteroaliphatic and aromatic/heteroaromatic).
Breadth summary
Within the fixed backbone (oxadiazole central unit, nitrocatechol-like moiety implied by the claim language, and pyridine N-oxide linkage), the claim gives high latitude on peripheral substituents (R4–R7) and on certain linker/heteroatom variables (Y, n, m).
That design typically:
- captures multiple close analogs without requiring an exact structure in the claims, and
- increases design-around difficulty because many substitution patterns remain within the enumerated substituent sets.
Which specific compound is expressly covered: the named example in claims 2, 4, 6, and 8
The claims repeatedly recite the same specific Formula (I) embodiment:
“5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol.”
Practical legal impact:
- It strengthens infringement posture for any product that uses this compound (or a salt thereof, if encompassed by “compound” interpretation in the relevant claim construction).
- It provides a clear “anchor” for novelty and for written description alignment within the Markush scope.
What are the method-of-use outcomes that drive infringement: brain L-DOPA delivery, peripheral COMT inhibition, and O-methylation reduction
Claim 1: increasing oral L-DOPA brain delivery
Claim 1 targets a specific therapeutic mechanism expressed as an outcome: “increasing the amount of orally administered L-DOPA which reaches the brain.”
Key infringement hook:
- a combination regimen where a patient receives oral L-DOPA plus an accused oral COMT inhibitor of Formula (I), with therapeutic intent to raise brain levels.
Claim 3: inhibiting COMT in the periphery
Claim 3 shifts from a brain-level outcome to an organ-system pharmacology concept: COMT inhibition “in the periphery.”
Key hook:
- if an accused regimen is positioned and dosed to produce peripheral COMT inhibition while treating PD, it aligns with Claim 3’s functional language.
Claim 7: reducing O-methylation of L-DOPA
Claim 7 targets a measurable biochemical endpoint: reducing O-methylation of L-DOPA.
Key hook:
- clinical/pharmacology evidence showing reduced O-methylation metabolites would map to the claim’s functional limitation.
Why these three are strategically linked
The three independent method claim concepts overlap in practice but are drafted to reduce reliance on any single proof track:
- Outcome in brain delivery (Claim 1),
- pharmacological site concept (Claim 3),
- biochemical mechanism (Claim 7).
What formulations and manufacturing steps are covered: does US 9,550,759 protect drug products or only methods?
Claim 5: method of manufacturing a pharmaceutical composition
Claim 5 is a manufacturing/formulation method claim:
- “method of manufacture of a pharmaceutical composition suitable for treatment of Parkinson’s disease”
- comprising formulating a Formula (I) compound with a pharmaceutically acceptable carrier.
Legal scope:
- This is not a standard product-by-process claim written as “a composition comprising X,” but it still can:
- be asserted against formulation/manufacturing activities for any ANDA or other product maker that produces a PD-appropriate dosage form containing Formula (I).
Dosage form breadth
The claim text you provided does not constrain dosage form (tablet, capsule, suspension, etc.). The carrier language is broad enough to cover most oral formulations unless the specification limits carrier/dosage elsewhere (not provided here).
How strong is US 9,550,759 against generic and reformulation: what would a design-around need to avoid?
Design-around pressure points
To avoid literal infringement, an accused product would generally need to break at least one of the claim’s structural or functional requirements:
- Formula (I) exclusion: change the compound such that it no longer fits the Markush definition (central unit P, pyridine N-oxide R3 connection/region, linker atoms n/m, or heteroatom Y set, or R4–R7 substituent sets).
- Functional limitation failure: for method claims, avoid administering an “effective amount” intended to increase brain delivery, inhibit peripheral COMT, or reduce O-methylation in the claimed PD context.
- Route and combination context: Claim 1 explicitly says “orally administered L-DOPA… reaches the brain,” which may be used to distinguish non-oral L-DOPA regimens or non-oral COMT inhibitor co-therapy.
Practical risk profile
Because the claim’s compound definition is broad and the method claims are not limited to specific dosing schedules or specific L-DOPA formulations, a generic challenger would face risk if their COMT inhibitor remains within Formula (I) and is administered in an oral regimen to PD patients receiving L-DOPA.
What Orange Book status applies to US 9,550,759: which FDA-listed drugs map to the COMT inhibitor claims?
No mapping from US 9,550,759 to a specific FDA product listing (Orange Book) is included in your prompt. Under your constraints, a complete and accurate Orange Book status determination cannot be produced from the provided information alone.
When does US 9,550,759 expire: patent term, PTA, and exclusivity timeline needs case data
No priority filing date, family data, or term-adjustment information is included in your prompt. A complete exclusivity/timeline analysis cannot be produced without those data.
What Paragraph IV challenges exist for US 9,550,759: litigation and settlement status
No litigation docket entries, settlement dates, or Paragraph IV filings are included in your prompt. A complete and accurate landscape of challenges against this specific US patent cannot be produced from the provided information alone.
Patent landscape depth: where 9,550,759 likely sits in the family relative to earlier composition claims and later formulation or derivative claims
Estate structure inference from claim set
Given the presence of:
- broad method-of-use claims (brain delivery, peripheral COMT inhibition, O-methylation reduction),
- a manufacturing/formulation method claim, and
- a Markush structure with many variable substituents,
US 9,550,759 likely functions as a central claims patent within a chemical family where the core inventive concept is the COMT-inhibitory nitrocatechol/oxadiazole/pyridine N-oxide architecture.
Adjacent claim clusters typically found in the same families
Without access to the specification, related US publications, and prosecution history, a fully accurate list of family members cannot be produced here. What can be said from the claim language alone is that the estate is oriented around:
- oral administration with L-DOPA in PD,
- COMT inhibition (peripheral and mechanistic),
- chemical variants within a defined scaffold.
Which companies are practicing or challenging the same chemical space: competitive landscape
Your prompt does not include applicant/assignee information for US 9,550,759, nor does it list any counterpart drugs, ANDA filers, or licensees. A company-by-company competitive analysis cannot be produced from the provided information alone.
What is the business implication for licensing: does 9,550,759 read on future COMT inhibitor candidates?
Licensing takeaways
- The broad Markush scaffold and functional method claims create a licensing environment where second-generation COMT inhibitors with minor substituent changes may still be captured.
- Any licensing or freedom-to-operate diligence would need to prioritize:
- compound structure compliance with Formula (I),
- oral co-administration strategies with L-DOPA,
- and PD-indication positioning tied to COMT inhibition outcomes.
Key Takeaways
- US 9,550,759 is a method-of-use and formulation/method-of-manufacture patent for orally administered Formula (I) COMT-inhibitory compounds in PD, tied to L-DOPA brain delivery, peripheral COMT inhibition, and reduction of L-DOPA O-methylation.
- The compound scope is broad: R4–R7 allow extensive substituent variability; P covers multiple oxadiazole regioisomers; and linker/heteroatom variables include Y in {O, NH, S} with n in {0–3} and m in {0–1}.
- A specific enumerated compound is explicitly covered in multiple claims, providing an infringement anchor.
- Design-around must break Formula (I) or avoid the functional outcome and claimed oral L-DOPA context; functional wording reduces reliance on a single pharmacology endpoint.
FAQs
-
Does US 9,550,759 require that the COMT inhibitor be co-administered with L-DOPA?
Claim 1 and Claim 7 expressly tie the method to PD patients receiving L-DOPA; Claim 3 ties to COMT inhibition in the periphery.
-
Are both oxadiazole regioisomer variants within the scope?
Yes. P includes regioisomers of 1,3,4-oxadiazol-2,5-diyl and 1,2,4-oxadiazol-3,5-diyl, and includes both realizable regioisomers by exchange of specified moieties.
-
Can the pyridine group vary in its N-oxide connectivity within the claims?
Yes. R3 is a pyridine N-oxide according to formulas A, B, or C connected by the unmarked bond.
-
Is there claim coverage for pharmaceutical manufacturing/formulation steps?
Yes. Claim 5 covers a method of manufacturing a PD-suitable pharmaceutical composition by formulating a Formula (I) compound with a pharmaceutically acceptable carrier.
-
How do claims 1, 3, and 7 differ in legal proof requirements?
Claim 1 focuses on brain L-DOPA delivery outcome; Claim 3 on site-specific “periphery” COMT inhibition; Claim 7 on reduction of L-DOPA O-methylation.
References
- US Patent 9,550,759 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
